About: Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate
Creator	Jahrling, Peter Luke, Thomas Wada, Jiro Postnikova, Elena Sullivan, Eddie Wu, Hua Bollinger, Laura Hensley, Lisa Honko, Anna Alter, Galit Olinger, Gene Jiao, Jin-An Khurana, Surender Glenn, Gregory Smith, Gale Pal, Subhamoy Byrum, Russell Mazur, Steven Oberlander, Nicholas Burdette, Tracey Dye, John Frey, Kenneth Gunn, Bronwyn Hamilton, Theron Hooper, Jay Ragland, Dan Janosko, Krisztina Bennett, Richard Bishop-Lilly, Kimberly Gerhardt, Dawn Claire, St, Marisa
topic	covid:25576dd63e9bdf1bef094279010e378d096d40f2#this
Source	Medline; PMC
abstract	Transchromosomic bovines (Tc-bovines) adaptively produce fully human polyclonal immunoglobulin (Ig)G antibodies after exposure to immunogenic antigen(s). The National Interagency Confederation for Biological Research and collaborators rapidly produced and then evaluated anti-Ebola virus IgG immunoglobulins (collectively termed SAB-139) purified from Tc-bovine plasma after sequential hyperimmunization with an Ebola virus Makona isolate glycoprotein nanoparticle vaccine. SAB-139 was characterized by several in vitro production, research, and clinical level assays using wild-type Makona-C05 or recombinant virus/antigens from different Ebola virus variants. SAB-139 potently activates natural killer cells, monocytes, and peripheral blood mononuclear cells and has high-binding avidity demonstrated by surface plasmon resonance. SAB-139 has similar concentrations of galactose-α-1,3-galactose carbohydrates compared with human-derived intravenous Ig, and the IgG1 subclass antibody is predominant. All rhesus macaques infected with Ebola virus/H.sapiens-tc/GIN/2014/Makona-C05 and treated with sufficient SAB-139 at 1 day (n = 6) or 3 days (n = 6) postinfection survived versus 0% of controls. This study demonstrates that Tc-bovines can produce pathogen-specific human Ig to prevent and/or treat patients when an emerging infectious disease either threatens to or becomes an epidemic.
has issue date	2018-12-15(xsd:dateTime)
bibo:doi	10.1093/infdis/jiy377
bibo:pmid	30010950
has license	cc-by-nc-nd
sha1sum (hex)	25576dd63e9bdf1bef094279010e378d096d40f2
schema:url	https://doi.org/10.1093/infdis/jiy377
resource representing a document's title	Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate
has PubMed Central identifier	PMC6249570
has PubMed identifier	30010950
schema:publication	J Infect Dis
resource representing a document's body	covid:25576dd63e9bdf1bef094279010e378d096d40f2#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/25576dd63e9bdf1bef094279010e378d096d40f2
is schema:about of	named entity 'NATURAL KILLER CELLS' named entity '1 DAY' named entity 'DAYS' named entity 'PATHOGEN' named entity 'TREATED WITH' named entity 'IMMUNOGLOBULIN' named entity 'HYPERIMMUNIZATION' named entity 'CARBOHYDRATES' named entity 'ANTIBODIES' named entity 'RAPIDLY' named entity 'SPECIFIC' named entity 'NATIONAL' named entity 'LEVEL' named entity 'IGG1' named entity 'CLINICAL' named entity 'EBOLA VIRUS' named entity 'ANTIGEN' named entity 'TREAT' named entity '28S' named entity 'IN VITRO' named entity 'PREDOMINANT' named entity 'ANTIBODY' named entity 'VARIANTS' named entity 'EVALUATED' named entity 'controls' named entity 'antigens' named entity 'immunoglobulin' named entity 'INFECTED' named entity 'BOVINES' named entity 'BIOLOGICAL RESEARCH' named entity 'GALACTOSE' named entity 'HIGH' named entity 'PLASMA' named entity '139' named entity 'SAPIENS' named entity 'PRODUCE' named entity 'IGG IMMUNOGLOBULINS' named entity 'SUFFICIENT' named entity 'TO PREVENT' named entity 'BINDING' named entity 'PRODUCTION' named entity 'INFECTIOUS DISEASES' named entity 'HUMAN IMMUNOGLOBULIN G' named entity 'ISOLATE' named entity 'JOURNAL ' named entity 'TREATS' named entity 'EBOLA VIRUS' named entity 'NONHUMAN PRIMATES'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software